Bruker Corporation

Bruker reported Q2 2026 revenue of $838.5 million, up 5.2% year over year; organic revenue growth was 2.8%, or 3.4% excluding U.S. tariff refunds. Non-GAAP gross margin was 52.1% versus 48.6% a year ago, non-GAAP operating margin was 14.1% versus 8.0%, and non-GAAP diluted EPS was $0.49 versus $0.32. On a GAAP basis, the company reported a diluted loss per share of $0.41 versus GAAP EPS of $0.05 in Q2 2025, reflecting a $135 million noncash goodwill impairment in automation and spatial biology. For the first half, revenue rose 3.9% to $1.66 billion. For FY26, management reaffirmed organic revenue growth of 1% to 2%, reported revenue of $3.54 billion to $3.57 billion, non-GAAP operating margin expansion of 250 to 300 basis points, and non-GAAP EPS of $2.10 to $2.15. They said Q3 organic revenue should be roughly flat to up slightly year over year, with a sequential margin/EPS dip, followed by a stronger Q4.

Frank Laukien emphasized that Bruker has returned to organic growth and is seeing improving demand across several end markets, especially biopharma, semi metrology, security detection and energy research. He stressed that the company is reorganizing around connected workflows with the new Bruker Biosystems Group and BMID structure to better align with customers and accelerate innovation. His tone was upbeat but measured, repeatedly pointing to delayed revenue recognition from longer lead-time deep tech orders and saying the company expects these orders to help Q4, 2027 and beyond.

Gerald Herman said Q2 results were at the low end of revenue expectations but meaningfully ahead on margins and EPS, helped by tariff refunds, cost savings, favorable mix and volume. He quantified tariff refunds as adding about 200 basis points to Q2 operating margin and about $0.06 to EPS, and said operating cash flow improved $50 million year over year while free cash flow improved about $43 million. Net leverage was 2.8x at June 30, 2026. He also said Bruker is on track for $140 million of annualized cost savings in 2026, with about $30 million delivered in Q2, and that the new operating structure should add about $20 million of additional cost reductions in FY27.

Analysts focused on tariff refunds, the sustainability and timing of semi metrology demand, the Q3-to-Q4 revenue shift, and whether margin expansion can continue into 2027. Management said tariff refunds were partly passed through to customers as contra revenue, were already baked into the full-year guide, and arrived earlier than expected in Q2. On semis, management described demand as sustainable through at least the next 6 quarters, with long lead times of 3 to 6 quarters or even 9 to 24 months in some deep tech projects; they also said bookings were up sequentially. Questions on U.S. academic/government weakness drew a response that U.S. orders remain weak, but Europe and China improved strongly, and management said a budget flush could help later in the year.